CLGN vs. TELA, NSPR, MLSS, VANI, CTSO, EDAP, ZYXI, APYX, HYPR, and ICCM
Should you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include TELA Bio (TELA), InspireMD (NSPR), Milestone Scientific (MLSS), Vivani Medical (VANI), Cytosorbents (CTSO), Edap Tms (EDAP), Zynex (ZYXI), Apyx Medical (APYX), Hyperfine (HYPR), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry.
CollPlant Biotechnologies vs. Its Competitors
CollPlant Biotechnologies (NASDAQ:CLGN) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
CollPlant Biotechnologies has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
TELA Bio has a net margin of -60.49% compared to CollPlant Biotechnologies' net margin of -2,680.00%. CollPlant Biotechnologies' return on equity of -77.05% beat TELA Bio's return on equity.
CollPlant Biotechnologies received 82 more outperform votes than TELA Bio when rated by MarketBeat users. However, 72.29% of users gave TELA Bio an outperform vote while only 60.17% of users gave CollPlant Biotechnologies an outperform vote.
21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 94.3% of TELA Bio shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 4.7% of TELA Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, TELA Bio had 2 more articles in the media than CollPlant Biotechnologies. MarketBeat recorded 5 mentions for TELA Bio and 3 mentions for CollPlant Biotechnologies. CollPlant Biotechnologies' average media sentiment score of 0.83 beat TELA Bio's score of 0.42 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.
CollPlant Biotechnologies presently has a consensus target price of $11.50, indicating a potential upside of 709.86%. TELA Bio has a consensus target price of $7.25, indicating a potential upside of 326.47%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe CollPlant Biotechnologies is more favorable than TELA Bio.
CollPlant Biotechnologies has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Summary
CollPlant Biotechnologies beats TELA Bio on 13 of the 19 factors compared between the two stocks.
Get CollPlant Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CollPlant Biotechnologies Competitors List
Related Companies and Tools
This page (NASDAQ:CLGN) was last updated on 6/15/2025 by MarketBeat.com Staff
Buy CLGN Stock Free CLGN Stock Alerts